TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Proposed combination enhances Pfizer’s position as a leading company in oncology
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)